Chugai Pharmaceutical (OTCMKTS:CHGCY) Posts Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) posted its quarterly earnings data on Thursday. The company reported $0.18 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 33.85% and a return on equity of 22.30%.

Chugai Pharmaceutical Trading Down 1.5 %

Shares of CHGCY stock traded down $0.30 on Thursday, reaching $20.33. 89,914 shares of the company’s stock were exchanged, compared to its average volume of 189,677. The company’s fifty day simple moving average is $21.62 and its 200 day simple moving average is $22.43. The stock has a market capitalization of $66.91 billion, a PE ratio of 26.06 and a beta of 0.81. Chugai Pharmaceutical has a 52 week low of $14.52 and a 52 week high of $26.00.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.